GILD is trading 3.1% up at $127.69 after the FDA approved its cancer drug Trodelvy for the first-line treatment of metastatic triple-negative breast cancer.

  • The label expansion establishes Trodelvy as a new backbone therapy regardless of PD-L1 status, significantly increasing the drug's addressable patient population.
  • This regulatory milestone materially expands GILD's market opportunity, driving investor optimism even as broader market indices trade lower.